Command Palette

Search for a command to run...

Preprint WatchMildJuly 28th, 2026

Neuropilin-1 functions as a proviral and immunoregulatory host factor during Chikungunya virus infection

Tung, K. S.; Mahish, C.; Ghosh, S.; Mukherjee, K.; Singh, S.; Bhowmick, B.; Khamaru, S.; Borasi, H.; Gaur, M.; Subudhi, B. B.; Chattopadhyay, S.; Chattopadhyay, S.

Neuropilin-1 promotes chikungunya virus infection and shapes the inflammatory host response, established with genetic, pharmacological and antibody blockade approaches in murine and human cell models.

Mild contradiction

1 prior failure

One documented clinical failure (Phase 1 or 2) overlaps with the claimed mechanism.

The preprint positions neuropilin-1 as a proviral and immunoregulatory host factor in chikungunya virus infection, using genetic, pharmacological and antibody blockade in murine and human cell models. Claidex records one NRP1 failure, certepetide-nrp1-cholangiocarcinoma-bolster-phase2-termination, classified as a translational mismatch in cholangiocarcinoma. The relevant read across is that NRP1 sits in several unrelated biological circuits, which is the property that makes tissue-selective engagement hard to achieve and makes an oncology mismatch unsurprising. A new antiviral indication does not inherit the oncology failure, and it does inherit the pleiotropy problem that any NRP1 blockade strategy has to solve.

Abstract excerpt

Neuropilin-1 (NRP1) is a transmembrane glycoprotein involved in angiogenesis, neurodevelopment, inflammation, cancer driven immune suppression, and immune homeostasis. However, its contribution to virus-induced immune responses is not explored. Chikungunya virus (CHIKV) is a re-emerging arthritogenic alphavirus that causes severe arthralgia, and myalgia, accompanied by heightened inflammatory cytokine responses. The host factors that drive these inflammatory responses, however, remain poorly defined. Here, in this current study, the role of NRP1 in CHIKV infection was investigated using in vitro, and in vivo model systems. Using genetic manipulation, pharmacological, and antibody blockade-mediated approaches in murine and human cellular infection models, it was demonstrated that NRP1 promotes CHIKV infection while restraining the production of proinflammatory cytokines. Furthermore, NRP1 inhibition selectively increased JNK phosphorylation. Hence, inhibiting JNK reduced the elevated cytokine production caused by NRP1 blockade. Moreover, NRP1 interacted with CHIKV-E1 and is involved in multiple phases of CHIKV infection. In addition, it was demonstrated that NRP1 inhibition using EG00229 trifluoroacetate can reduce viral infection in several CHIKV-susceptible cells, human peripheral blood macrophages, and in the in vivo mice model of infection. Together, these findings indicate that NRP1 is an important host factor and a probable therapeutic target during CHIKV infection.

Matching Claidex post-mortems

1 of 1 indexed

This is an automated contradiction flag, not an editorial judgment on the preprint's quality. Flags identify where the preclinical literature and the clinical failure record diverge.